Pills masthead

Archives: Search / 2020 / 2019 / 2018 / 2017 / 2016 / 2015 / 2014 / 2013 / 2012

2011201020092008200720062004

 
From
To
Dec 7, 2020
Lannett Announces New $30 Million Revolving Credit Facility

Lannett Company, Inc. (NYSE: LCI) today announced the closing of a $30 million asset-backed revolving credit facility with Wells Fargo Bank, National Association. "Completing this transaction...

More
Nov 30, 2020
Lannett Pays Off, In Full, Remaining Term A Loans

Lannett Company, Inc. (NYSE: LCI) today announced that the company used a portion of its existing cash on hand to pay off, in full, the remaining $42 million outstanding balance of its Term A...

More
Nov 4, 2020
Lannett Announces Fiscal 2021 First-quarter Financial Results; Affirms Guidance

Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2021 first quarter ended September 30, 2020. "We view our fiscal 2021 first quarter net sales of $126 million as a...

More
Nov 3, 2020
Lannett Launches Authorized Generic of Tirosint® (Levothyroxine Sodium Capsules)

Lannett Company, Inc. (NYSE: LCI) today announced that it has commenced the launch of the authorized generic of Tirosint® (Levothyroxine Sodium Capsules USP). Lannett entered into an exclusive...

More
Oct 28, 2020
Lannett To Report Fiscal 2021 First-Quarter Financial Results, Host Conference Call On Wednesday, November 4

Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2021 first quarter on Wednesday, November 4, 2020, after the market closes. Lannett...

More
Aug 26, 2020
Lannett Announces Fiscal 2020 Fourth-Quarter, Full-Year Financial Results

Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2020 fourth quarter and full year ended June 30, 2020. "For both the fiscal 2020 full year and fourth quarter, our...

More
Aug 19, 2020
Lannett To Report Fiscal 2020 Fourth-Quarter, Full-Year Financial Results, Host Conference Call On Wednesday, August 26

Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2020 fourth quarter and full year on Wednesday, August 26, 2020, after the market closes....

More
Aug 17, 2020
Lannett Announces Notice Of Proposed Settlement And Dismissal With Prejudice Of Derivative Action

Lannett Company, Inc. (NYSE: LCI) today announced the Notice of Proposed Settlement and Dismissal with Prejudice of Derivative Action (the "Notice"), a copy of which is attached hereto as an...

More
Aug 17, 2020
Lannett Signs Agreement To Be Exclusive Distributor Of Generic Flovent® Diskus®

Lannett Company, Inc. (NYSE: LCI) today announced that it has entered into an exclusive U.S. distribution agreement for the therapeutically equivalent generic of Flovent® Diskus® (Fluticasone...

More
Aug 3, 2020
Lannett Announces Launch Of FDA Approved Levothyroxine Tablets

Lannett Company, Inc. (NYSE: LCI) today announced the launch of Cediprof, Inc.'s FDA approved Levothyroxine Sodium Tablets USP, under the companies recently announced interim exclusive supply and...

More
Jul 27, 2020
Lannett To Launch Levorphanol Tablets

Lannett Company, Inc. (NYSE: LCI) today announced that it will soon launch Levorphanol Tablets 2 mg, a partnered product. Lannett entered into an exclusive U.S. distribution agreement for...

More
Jul 23, 2020
Lannett Launches Mexiletine HCl Capsules

Lannett Company, Inc. (NYSE: LCI) today announced that it has launched Mexiletine Hydrochloride Capsules 150 mg, 200 mg and 250 mg, a partnered product. Mexiletine Hydrochloride Capsules is the...

More
Jul 16, 2020
Lannett And Cediprof Announce Exclusive Distribution Agreement For An Approved Levothyroxine

Lannett Company, Inc. (NYSE: LCI) and Cediprof, Inc., a part of the Neolpharma Pharmaceutical Group family of companies, today said that the companies have entered into an interim exclusive supply...

More
Jul 13, 2020
Lannett Announces Restructuring, Cost Reduction Initiatives

Lannett Company, Inc. (NYSE: LCI) today announced a restructuring and cost savings plan. The initiatives include consolidating the research and development (R&D) function into a single location in...

More
Jun 11, 2020
Lannett Provides Update On Clinical Advancement Of Biosimilar Insulin Glargine, Following FDA Meeting

Lannett Company, Inc. (NYSE: LCI) today said that representatives from the company spoke with and received guidance from the U.S. Food and Drug Administration (FDA) on the clinical advancement...

More
May 6, 2020
Lannett Announces Fiscal 2020 Third-Quarter Financial Results

Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2020 third quarter ended March 31, 2020. "I am incredibly proud of the effort and dedication of all of our...

More
Apr 29, 2020
Lannett To Report Fiscal 2020 Third-Quarter Financial Results, Host Conference Call On Wednesday, May 6

Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2020 third quarter on Wednesday, May 6, 2020, after the market closes. Lannett management...

More
Apr 8, 2020
Lannett To Meet With FDA Regarding The Clinical Advancement Of Biosimilar Insulin Glargine On June 9

Lannett Company, Inc. (NYSE: LCI) today announced that it is set to meet with the U.S. Food and Drug Administration (FDA) on June 9, 2020 to plan next steps for the clinical advancement of its...

More
Apr 7, 2020
Philadelphia drug maker poised to ramp up production of possible COVID-19 therapy

Lannett in the News – Philadelphia Business Journal, April 7, 2020

More
Mar 31, 2020
Lannett Begins Marketing Generic Adderall® XR

Lannett Company, Inc. (NYSE: LCI) today announced that it has commenced marketing a generic version of Adderall XR®, an extended-release mixed salt of a single entity Amphetamine capsule product...

More
Mar 9, 2020
Lannett To Present At The 32nd annual Roth Conference On March 16

Lannett Company, Inc. (NYSE: LCI) today announced that the company will present at the 32nd Annual ROTH Conference on March 16, 2020 at 2:30 p.m. PT at The Ritz Carlton, in Laguna Niguel,...

More
Feb 5, 2020
Lannett Announces Fiscal 2020 Second-Quarter Financial Results

Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2020 second quarter ended December 31, 2019. "For our fiscal 2020 second quarter, strong sales across multiple...

More
Jan 30, 2020
Lannett To Report Fiscal 2020 Second-Quarter Financial Results, Host Conference Call On Wednesday, February 5

Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2020 second quarter on Wednesday, February 5, 2020, after the market closes. Lannett...

More
Jan 13, 2020
Lannett Announces FDA Approval Of NDA For Branded Anesthetic Product, Cocaine Hydrochloride Nasal Solution 4%

Lannett Company, Inc. (NYSE: LCI) today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA), submitted under the 505(b)(2) regulatory pathway,...

More
Jan 6, 2020
Lannett Launches Venlafaxine ER Tablets And Lidocaine Topical Solution 4%

Lannett Company, Inc. (NYSE: LCI) today announced that it has commenced marketing Venlafaxine Extended Release (ER) Tablets, 150 mg and 225 mg, USP, and Lidocaine Topical Solution 4%. The...

More
1-25      26-50      51-75      76-100      101-125      126-150      151-175      176-200      201-225      226-250      251-275      276-300      301-325      326-350      351-375      376-400      401-425      426-450      451-475      476-500      501-525      526-550      551-575      576-600      601-625      626-650      651-662
Price Data
NYSELCI